{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T23:08:00Z","timestamp":1648681680908},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T00:00:00Z","timestamp":1442966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0138503","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T18:09:19Z","timestamp":1443031759000},"page":"e0138503","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01508286","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antonia","family":"Lepida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djamal","family":"Abdurakhmanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Abrao Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mangia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafae","family":"Iraqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"DeMasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lonjon-Domanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","article-title":"Chronic Hepatitis C Infection","volume":"364","author":"HR Rosen","year":"2011","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cld.2006.08.012","article-title":"Hepatitis C virus and liver transplantation","volume":"10","author":"EC Verna","year":"2006","journal-title":"Clin Liver Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"TR Morgan","year":"2010","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"LI Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"AJ van der Meer","year":"2012","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Eng J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Eng J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Eng J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Eng J Med"},{"issue":"Suppl 1","key":"ref10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/liv.12391","article-title":"Management of HCV patients with cirrhosis with direct acting antivirals","volume":"34","author":"V Boccaccio","year":"2014","journal-title":"Liver Int"},{"key":"ref11","first-page":"374A","article-title":"Efficacy and safety of telaprevir-based regiments in cirrhotic patients with HCV genotype 1 and prior peginterferon\/ribavirin treatment failure: subanalysis of the REALIZE phase III study","volume":"54","author":"S Pol","year":"2011","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","article-title":"Efficacy and safety of boceprevir plus peginterferon-ribavirin patients with HCV G1 infection and advanced fibrosis\/cirrhosis","volume":"58","author":"S Bruno","year":"2013","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/gutjnl-2013-305667","article-title":"Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C","volume":"63","author":"M Colombo","year":"2014","journal-title":"Gut"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French Early Access Programme (ANRS CO20-CUPIC)\u2014NCT01514890","volume":"59","author":"C H\u00e9zode","year":"2013","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jvh.12145","article-title":"Efficacy and safety of telaprevir (TVR) triple therapy in a TVR) triple therapy in a with HCV genotype 1: interim analysis after 24 weeks of treatment","volume":"21","author":"CR Werner","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/apt.12718","article-title":"Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis","volume":"39","author":"V Saxena","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"ref17","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60067-7","article-title":"Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease-predictive factors for sepsis","volume":"58","author":"K Rutter","year":"2013","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12546","article-title":"Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort","volume":"39","author":"LI Backus","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26602","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","volume":"59","author":"S Mauss","year":"2014","journal-title":"Hepatology"},{"key":"ref20","first-page":"87","article-title":"Safety and efficacy of protease inhibitor based combination therapy in a single-center &quot;real-life&quot; cohort of 110 patients with chronic hepatitis C genotype 1 infection","volume":"14","author":"MH Wehmeyer","year":"2014","journal-title":"J Viral MSD. Transgene. Grant support: RBMC Gastroenterol"},{"key":"ref21","first-page":"1038A","article-title":"First real-life data of triple therapy with telaprevir (TVR) and boceprevir (BOC) in combination with peginterferon-alfa-2a (PEG) plus ribavirin (RBV) in patients infected with chronic hepatitis C (CHC) genotype 1 in a non-interventional study (PAN) in Germany","volume":"S56","author":"N Forestier","year":"2012","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e55285","DOI":"10.1371\/journal.pone.0055285","article-title":"Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting","volume":"8","author":"B Maasoumy","year":"2013","journal-title":"PLoS ONE"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jhep.2010.07.033","article-title":"Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy","volume":"54","author":"EA Tsochatzis","year":"2011","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"J Foucher","year":"2006","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.21420","article-title":"Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases","volume":"44","author":"N Ganne-Carri\u00e9","year":"2006","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elestography","volume":"48","author":"L Castera","year":"2008","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.21665","article-title":"Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis","volume":"45","author":"F Vizzutti","year":"2007","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jhep.2011.01.051","article-title":"Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study","volume":"55","author":"MA Robic","year":"2011","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1365-2893.2011.01493.x","article-title":"Transient elastography for predicting clinical outcomes in patients with chronic liver disease","volume":"19","author":"DA Klibansky","year":"2012","journal-title":"J Viral Hepatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2893.2008.01055.x","article-title":"Changes of non-invasive markers and FibroScan values during HCV treatment","volume":"16","author":"J Vergniol","year":"2009","journal-title":"J Viral Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3748\/wjg.v17.i41.4581","article-title":"FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus","volume":"17","author":"K Patel","year":"2011","journal-title":"World J Gastroenterol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","article-title":"Liver stiffness diminishes with antiviral response in chronic hepatitis C","volume":"34","author":"C H\u00e9zode","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","article-title":"The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin","volume":"83","author":"E Ogawa","year":"2009","journal-title":"Antiviral Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP1570","article-title":"Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies","volume":"15","author":"T Poynard","year":"2010","journal-title":"Antivir Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.dld.2013.03.023","article-title":"Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C","volume":"45","author":"C Stasi","year":"2013","journal-title":"Dig Liver Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1872-034X.2009.00618.x","article-title":"Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C","volume":"40","author":"Y Arima","year":"2010","journal-title":"Hepatol Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/jac\/dkq272","article-title":"Changes of liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin","volume":"65","author":"J Mac\u00edas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1440-1746.2009.06194.x","article-title":"Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan","volume":"25","author":"JH Wang","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e47715","DOI":"10.1371\/journal.pone.0047715","article-title":"Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy","volume":"7","author":"SM Martinez","year":"2012","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4321\/S1130-01082010000700005","article-title":"Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy","volume":"102","author":"J Mendoza","year":"2010","journal-title":"Rev Esp Enferm Dig"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective Comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the Assessment of Fibrosis in Chronic Hepatitis C","volume":"128","author":"L Cast\u00e9ra","year":"2005","journal-title":"Gastroenterol"},{"key":"ref43","article-title":"Table for grading the severity of adult and pediatric adverse events","year":"2004"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2014.06.005","article-title":"Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program","volume":"61","author":"M Colombo","year":"2014","journal-title":"J Hepatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4254\/wjh.v6.i9.660","article-title":"Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients","volume":"6","author":"D Bonnet","year":"2014","journal-title":"World J Hepatol"},{"issue":"Suppl 1","key":"ref46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1478-3231.2011.02702.x","article-title":"Future treatment of patients with HCV cirrhosis","volume":"32","author":"M Bourliere","year":"2012","journal-title":"Liver Int"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-7-40","article-title":"Meta-analyses of FibroTest diagnostic value in chronic liver disease","volume":"7","author":"T Poynard","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","author":"R Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1155\/2013\/684982","article-title":"A health technology assessment of transient elastography in adult liver disease","volume":"27","author":"R Steadman","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jhep.2012.04.025","article-title":"Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population","volume":"57","author":"T Poynard","year":"2012","journal-title":"J Hepatol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"T Poynard","year":"2013","journal-title":"J Hepatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1373\/clinchem.2006.070961","article-title":"A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C","volume":"52","author":"Y Ngo","year":"2006","journal-title":"Clin Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1053\/j.gastro.2011.02.058","article-title":"Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C","volume":"140","author":"J Vergniol","year":"2011","journal-title":"Gastroenterology"},{"key":"ref54","first-page":"445","article-title":"Prognostic value of liver fibrosis biomarkers: a meta-analysis","volume":"7","author":"T Poynard","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3748\/wjg.v19.i12.1890","article-title":"Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives","volume":"19","author":"BK Kim","year":"2013","journal-title":"World J Gastroenterol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0138503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:27:05Z","timestamp":1540031225000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0138503"}},"subtitle":[],"editor":[{"given":"Vincent","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,23]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0138503","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,23]]}}}